Status: Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Participants needed: 262
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: IDEAYA BiosciencesUpdated: Jul 9, 2026Locations: 13
Eligibility criteria
Are willing to participate in this clinical study, understand the study procedur... [+15]
Have mixed SCLC and NSCLC histology are not allowed (SCLC with components of lar... [+26]